Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.
Antoinette R. Tan, MD, MHSc, discusses the promise of oral selective estrogen receptor degraders as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.
Dr. Vivek Subbiah to Serve as Chief, Early-Phase Drug Development Across SCRI's Research Network Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations